FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bu	ırden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Shukla Sanjay					2. Issuer Name and Ticker or Trading Symbol aTYR PHARMA INC [LIFE]							ck all applica Director Officer (able)			/ner		
(Last) (First) (Middle) 3545 JOHN HOPKINS COURT, SUITE #250					3. Date of Earliest Transaction (Month/Day/Year) 02/06/2019								President and CEO					
(Street)			92121		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc Line)							
(City)	(S	itate)	(Zip)															
		Ta	ble I - Non-D	Derivat	ive S	ecuritie	s Ac	quired, E	Disp	osed o	f, or Be	neficially	Owned					
Date			Transact ate Ionth/Day	Execution Date,		Code (In			ties Acquire d Of (D) (Ins	ed (A) or tr. 3, 4 and 5	5. Amoun Securities Beneficial Owned Fo	Formula (D) (I) (I) (I) (I) (I)		Direct Indirect I	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution Date, Tr y or Exercise (Month/Day/Year) if any C		Code	nsaction Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and of Securiti Underlying Derivative (Instr. 3 and			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported	s s llly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				Code	e V	(A)	(D)	Date Exercisable		opiration ate	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)				
Employee Stock Option (right to buy)	\$0.5172	02/06/2019		A		200,000		(1)	02	2/06/2029	Common Stock	200,000	\$0.00	200,00	00	D		
Restricted Stock Unit	(2)	02/06/2019		A		50,000		(3)		(3)	Common Stock	50,000	\$0.00	50,00	0	D		

Explanation of Responses:

- 1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2019, such that this option will be fully exercisable on February 6, 2023. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
- 2. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
- 3. The RSUs are scheduled to vest in two equal annual installments beginning on February 6, 2020, such that the RSUs will fully vest on February 6, 2021. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

Remarks:

Nancy D. Krueger, attorney-in**fact**

02/08/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.